Literature DB >> 29118164

Evaluation of In-House and Commercial Serological Tests for Diagnosis of Human Tularemia.

Hadjila Yanes1, Aurélie Hennebique1,2, Isabelle Pelloux1,2, Sandrine Boisset1,2, Dominique J Bicout2, Yvan Caspar1,2, Max Maurin3,2.   

Abstract

Tularemia is a zoonosis caused by the bacterium Francisella tularensis Its specific diagnosis remains based on serological methods, while F. tularensis is rarely detected in clinical samples by culture or PCR. The aim of the present study was to evaluate the performance of the Serion enzyme-linked immunosorbent assay (ELISA) classic Francisella tularensis IgG and IgM tests (Virion/Serion GmbH Institute, Würzburg, Germany) and the VIRapid tularemia immunochromatographic test (ICT) (Vircell, Granada, Spain) compared to that of the in-house microagglutination test (MAT) and indirect immunofluorescence assay (IFA) currently used at the French National Reference Center for Francisella We evaluated 256 consecutive sera from 208 patients, including 51 confirmed and 23 probable tularemia cases, and 134 control patients not infected with F. tularensis The IFA tests displayed 72.5% sensitivity for IgM (cutoff titer ≥80) and 74.5% for IgG (cutoff titer ≥160), and 99.3% specificity for both IgM and IgG. Using cutoffs advocated by the manufacturer, the Serion ELISAs displayed 88.2% sensitivity for IgM and 86.3% for IgG antibodies; specificity was 94.8% for IgM and 95.5% for IgG. Compared to MAT and IFA tests, the Serion ELISAs allowed earlier detection of specific antibodies (1 to 2 weeks versus 2 to 3 weeks after the onset of symptoms). The ICT sensitivity and specificity were 90% and 83.6%, respectively, when considering the cutoff advocated by the manufacturer. In conclusion, the Serion ELISAs are useful as screening tests for tularemia diagnosis, but additional confirmatory tests (such as MAT and IFA) are needed, especially in areas of low endemicity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ELISA; Francisella tularensis; immunochromatography; immunofluorescence assay; serology; tularemia; zoonosis

Mesh:

Substances:

Year:  2017        PMID: 29118164      PMCID: PMC5744216          DOI: 10.1128/JCM.01440-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Microagglutination test for early and specific serodiagnosis of tularemia.

Authors:  T Sato; H Fujita; Y Ohara; M Homma
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

2.  Human tularemia in France, 2006-2010.

Authors:  Max Maurin; Isabelle Pelloux; Jean Paul Brion; Jeanne-Noëlle Del Banõ; Aleth Picard
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

3.  Kinetics of the immune response associated with tularemia: comparison of an enzyme-linked immunosorbent assay, a tube agglutination test, and a novel whole-blood lymphocyte stimulation test.

Authors:  Henrik Eliasson; Per Olcén; Anders Sjöstedt; Margareta Jurstrand; Erik Bäck; Sören Andersson
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

4.  Francisella tularensis as a potential agent of bioterrorism?

Authors:  Max Maurin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-11-21       Impact factor: 5.091

Review 5.  The status of tularemia in Europe in a one-health context: a review.

Authors:  G Hestvik; E Warns-Petit; L A Smith; N J Fox; H Uhlhorn; M Artois; D Hannant; M R Hutchings; R Mattsson; L Yon; D Gavier-Widen
Journal:  Epidemiol Infect       Date:  2014-09-30       Impact factor: 4.434

6.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

7.  Specific recognition of the major capsid protein of Acanthamoeba polyphaga mimivirus by sera of patients infected by Francisella tularensis.

Authors:  Nicolas Pelletier; Didier Raoult; Bernard La Scola
Journal:  FEMS Microbiol Lett       Date:  2009-06-03       Impact factor: 2.742

8.  Immunity against Francisella tularensis in northern Finland.

Authors:  P Koskela; E Herva
Journal:  Scand J Infect Dis       Date:  1982

9.  Comparative analysis of antibodies to Francisella tularensis antigens during the acute phase of tularemia and eight years later.

Authors:  L Bevanger; J A Maeland; A I Kvan
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

10.  Francisella tularensis subspecies holarctica, Tasmania, Australia, 2011.

Authors:  Justin Jackson; Alistair McGregor; Louise Cooley; Jimmy Ng; Mitchell Brown; Chong Wei Ong; Catharine Darcy; Vitali Sintchenko
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

View more
  4 in total

1.  A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas.

Authors:  Alessandra Balestra; Hekuran Bytyci; Caroline Guillod; Antonio Braghetti; Luigia Elzi
Journal:  Int Med Case Rep J       Date:  2018-11-12

2.  Development and evaluation of a rapid RPA/CRISPR-based detection of Francisella tularensis.

Authors:  Jian-Hao Xu; Lin Kang; Bing Yuan; Zi-Han Feng; Shi-Qing Li; Jing Wang; Ya-Ru Wang; Wen-Wen Xin; Shan Gao; Jia-Xin Li; Yan-Song Sun; Jing-Lin Wang; Yuan Yuan
Journal:  Front Microbiol       Date:  2022-08-10       Impact factor: 6.064

Review 3.  Francisella tularensis, Tularemia and Serological Diagnosis.

Authors:  Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2020-10-26       Impact factor: 5.293

4.  Isolation of Francisella tularensis from Skin Ulcer after a Tick Bite, Austria, 2020.

Authors:  Mateusz Markowicz; Anna-Margarita Schötta; Freya Penatzer; Christoph Matscheko; Gerold Stanek; Hannes Stockinger; Josef Riedler
Journal:  Microorganisms       Date:  2021-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.